Sanofi nabs new use for Taxotere

Sanofi-Aventis won the FDA's nod for a new use for its cancer drug Taxotere. Now it can be marketed for use in head and neck cancers. Clinical trials had shown that Taxotere plus standard chemo boosted survival rate by more than three years. The drug has already been approved in the U.S. and Europe for breast, lung, prostate, and gastric cancers.

- see Sanofi's release